Bone Marrow Clinical Trials

69 recruitingLast updated: May 21, 2026

There are 69 actively recruiting bone marrow clinical trials across 11 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Bone Marrow Trials at a Glance

69 actively recruiting trials for bone marrow are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 24 trials, with the heaviest enrollment activity in Boston, Houston, and Philadelphia. Lead sponsors running bone marrow studies include M.D. Anderson Cancer Center, Massachusetts General Hospital, and Children's Hospital of Philadelphia.

Browse bone marrow trials by phase

About Bone Marrow Clinical Trials

Looking for clinical trials for Bone Marrow? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bone Marrow trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bone Marrow clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 1

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting

Cancer in Inherited Bone Marrow Failure Syndromes

Diamond-Blackfan AnemiaDyskeratosis CongenitaFanconi Anemia+2 more
National Cancer Institute (NCI)4,000 enrolled2 locationsNCT00027274
Recruiting

Study of Factors Regulating Mast Cell Proliferation

MastocytosisMonoclonalBone Marrow+1 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00044122
Recruiting

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Severe Aplastic AnemiaTelomere Biology DisordersInherited Bone Marrow Failure Syndromes
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT05012111
Recruiting
Phase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

Breast CancerBone Marrow Suppression
Hongxia Wang60 enrolled1 locationNCT07578064
Recruiting
Phase 2

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

Graft-Versus-Host-Disease (GVHD)Bone Marrow Transplantation
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine82 enrolled1 locationNCT07570745
Recruiting
Phase 1Phase 2

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Not Applicable

Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation

GvHDBone Marrow Transplant Complications
Scripps Health60 enrolled1 locationNCT06590285
Recruiting
Phase 1Phase 2

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid LeukemiaBlasts More Than 5 Percent of Bone Marrow Nucleated CellsPersistent Disease
Ohio State University Comprehensive Cancer Center28 enrolled2 locationsNCT04049539
Recruiting
Phase 1Phase 2

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Not Applicable

Focused Extracorporeal Shockwave Therapy for Knee Arthritis

Knee OsteoarthritisKnee Pain ChronicBone Marrow Edema
Kessler Foundation15 enrolled2 locationsNCT05596591
Recruiting
Phase 2

MAGIC Ruxolitinib for aGVHD

Acute Graft Versus Host Diseaseadverse effectsAllogeneic Bone Marrow Transplantation
John Levine98 enrolled14 locationsNCT06936566
Recruiting
Phase 2

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Acute Myeloid LeukemiaAMLMDS+4 more
Franziska Wachter37 enrolled2 locationsNCT05796570
Recruiting
Not Applicable

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

Sexual DysfunctionStem Cell Transplant ComplicationsBone Marrow Transplant Complications
Massachusetts General Hospital300 enrolled3 locationsNCT06541002
Recruiting
Phase 1

Nucleoside Therapy in Patients With Telomere Biology Disorders

Dyskeratosis CongenitaTelomere Biology DisordersHoyeraal-Hreidarsson Syndrome+4 more
Suneet Agarwal36 enrolled1 locationNCT06817590
Recruiting

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Fanconi AnemiaInherited Bone Marrow Failure Syndrome
National Cancer Institute (NCI)200 enrolled1 locationNCT05687149